Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Mast cell activation syndromes (MCASs) are defined by systemic severe and recurrent mast cell activation, usually in form of anaphylaxis, a substantial, event-related increase of the serum tryptase level beyond the individual’s baseline and a response of the symptomatology to drugs directed against mast cells, mast cell-derived mediators, or mediator effects. A number of predisposing genetic conditions, underlying allergic and other hypersensitivity states, and related comorbidities can contribute to the clinical manifestation of MCASs. These conditions include hereditary alpha tryptasemia, mastocytosis with an expansion of clonal KIT-mutated mast cells, atopic diathesis, and overt IgE-dependent and IgE-independent allergies. Several of these conditions have overlapping definitions and diagnostic criteria and may also develop concomitantly in the same patient. However, although criteria and clinical features overlap, each of these conditions is characterized by a unique constellation of variables and diagnostic criteria. Since two, three, or more conditions can coexist in the same patient, with obvious clinical implications, it is of crucial importance to diagnose the variant of MCAS precisely and to take all accompanying, underlying and potentially complicating conditions, and comorbidities into account when establishing the management plan. Indeed, most of these patients require multidisciplinary investigations and only a personalized treatment approach can lead to an optimal management plan providing an optimal quality of life and low risk of anaphylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MCAS is defined by severe recurrent systemic symptoms related to MCA, which resemble anaphylaxis.8,9,13”
From Mast cell activation syndrome: Current understanding and research needs (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These criteria were developed by consensus based on literature review and expert opinion, have been validated, and are considered standard.6–9”
From Mast cell activation syndrome: Current understanding and research needs (2024) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A tryptase > 20 ng/mL serves as a minor criterion to diagnose systemic mastocytosis and an increase in tryptase > 20% + 2 during an acute event is a required criterion in the diagnosis of mast cell activation syndrome.”
From Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders (2023) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, MCAS has been reported in patients with hereditary a-tryptasemia (HaT), an autosomal dominant genetic trait caused by an increased copy-number of the atryptase gene TPSAB1, resulting in increased baseline serum tryptase levels.7,8”
From Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders (2024) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 816
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Allan Bock, S., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.01.018 · Cited by 748
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationBrockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Self-citationMast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citation
Cited by
Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond
Vitte, J., Vibhushan, S., Bratti, M., Montero-Hernández, J. E., & Blank, U. (2022) · Medical Principles and Practice · doi:10.1159/000527481 · Cited by 126
Allergy: Mechanistic insights into new methods of prevention and therapy
Akdiş, C. A., Akdiş, M., Boyd, S. D., Sampath, V., Galli, S. J., & Nadeau, K. C. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add2563 · Cited by 87
The international consensus classification of mastocytosis and related entities
Leguit, R. J., Wang, S. A., George, T. I., Tzankov, A., & Orazi, A. (2023) · Virchows Archiv · doi:10.1007/s00428-022-03423-3 · Cited by 65
“Five different variants of MCAS are presently being recognized [3, 4]:”
BackgroundInfluentialTheoharides, T. C., Twahir, A., & Kempuraj, D. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.10.032 · Cited by 60
Mast cell activation syndrome: Current understanding and research needs
Castells, M., Giannetti, M. P., Hamilton, M. J., Novak, P., Pozdnyakova, O., Nicoloro-SantaBarbara, J., Jennings, S. V., Francomano, C., Kim, B., Glover, S. C., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.05.025 · Cited by 45
Self-citation
Metadata
- Authors
- Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K.
- Affiliations
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Basel (CH)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Gdańsk Medical University (PL)
- University of Salerno (IT)
- Pitié-Salpêtrière Hospital (FR)
- Helmholtz Munich (DE)
- Corresponding author
- Valent, Peter
- ORCID
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2022
- Volume
- 183
- Issue
- 7
- Pages
- 693-705
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- PMC
- PMC9393812
- OpenAlex
- W4281392104
- Cited by
- 55
- References
- 104
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 14 · 2023: 19 · 2022: 3
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- International Archives of Allergy and Immunology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- mast cell activation syndrome, anaphylaxis, serum tryptase, hereditary alpha-tryptasemia, mastocytosis, KIT mutations, atopy, IgE-dependent allergy, comorbidities, diagnostic criteria, mast cell stabilizers, personalized treatment
- MeSH terms
- Mast Cell Activation Syndrome, Anaphylaxis, Humans, Immunoglobulin E, Mast Cells, Mastocytosis, Quality of Life, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. https://app.cochat.ai/papers/10.1159/000524532
- The paper
- Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022). Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022. International Archives of Allergy and Immunology. https://doi.org/10.1159/000524532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.